Cargando…
Exploring the role of drug-metabolising enzymes in antidepressant side effects
RATIONALE: Cytochrome P450 enzymes are important in the metabolism of antidepressants. The highly polymorphic nature of these enzymes has been linked to variability in antidepressant metabolism rates, leading to hope regarding the use of P450 genotyping to guide treatment. However, evidence that P45...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480333/ https://www.ncbi.nlm.nih.gov/pubmed/25761838 http://dx.doi.org/10.1007/s00213-015-3898-x |
_version_ | 1782378144802537472 |
---|---|
author | Hodgson, Karen Tansey, Katherine E. Uher, Rudolf Dernovšek, Mojca Zvezdana Mors, Ole Hauser, Joanna Souery, Daniel Maier, Wolfgang Henigsberg, Neven Rietschel, Marcella Placentino, Anna Craig, Ian W. Aitchison, Katherine J. Farmer, Anne E. Dobson, Richard J. B. McGuffin, Peter |
author_facet | Hodgson, Karen Tansey, Katherine E. Uher, Rudolf Dernovšek, Mojca Zvezdana Mors, Ole Hauser, Joanna Souery, Daniel Maier, Wolfgang Henigsberg, Neven Rietschel, Marcella Placentino, Anna Craig, Ian W. Aitchison, Katherine J. Farmer, Anne E. Dobson, Richard J. B. McGuffin, Peter |
author_sort | Hodgson, Karen |
collection | PubMed |
description | RATIONALE: Cytochrome P450 enzymes are important in the metabolism of antidepressants. The highly polymorphic nature of these enzymes has been linked to variability in antidepressant metabolism rates, leading to hope regarding the use of P450 genotyping to guide treatment. However, evidence that P450 genotypic differences underlie the variation in treatment outcomes is inconclusive. OBJECTIVES: We explored the links between both P450 genotype and serum concentrations of antidepressant with antidepressant side effects, using data from the Genome-Based Therapeutic Drugs for Depression Project (GENDEP), which is a large (n = 868), pharmacogenetic study of depressed individuals treated with escitalopram or nortriptyline. METHODS: Patients were genotyped for the enzymes CYP2C19 and CYP2D6, and serum concentrations of both antidepressant and primary metabolite were measured after 8 weeks of treatment. Side effects were assessed weekly. We investigated associations between P450 genotypes, serum concentrations of antidepressants and side effects, as well as the relationship between P450 genotype and study discontinuation. RESULTS: P450 genotype did not predict total side effect burden (nortriptyline: n = 251, p = 0.5638, β = −0.133, standard error (SE) = 0.229; escitalopram: n = 340, p = 0.9627, β = −0.004, SE = 0.085), study discontinuation (nortriptyline n = 284, hazard ratio (HR) = 1.300, p = 0.174; escitalopram n = 376, HR = 0.870, p = 0.118) or specific side effects. Serum concentrations of antidepressant were only related to a minority of the specific side effects measured: dry mouth, dizziness and diarrhoea. CONCLUSIONS: In this sample where antidepressant dosage is titrated using clinical judgement, P450 genotypes do not explain differences between patients in side effects with antidepressants. Serum drug concentrations appear to only explain variability in the occurrence of a minority of specific side effects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-015-3898-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4480333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-44803332015-07-01 Exploring the role of drug-metabolising enzymes in antidepressant side effects Hodgson, Karen Tansey, Katherine E. Uher, Rudolf Dernovšek, Mojca Zvezdana Mors, Ole Hauser, Joanna Souery, Daniel Maier, Wolfgang Henigsberg, Neven Rietschel, Marcella Placentino, Anna Craig, Ian W. Aitchison, Katherine J. Farmer, Anne E. Dobson, Richard J. B. McGuffin, Peter Psychopharmacology (Berl) Original Investigation RATIONALE: Cytochrome P450 enzymes are important in the metabolism of antidepressants. The highly polymorphic nature of these enzymes has been linked to variability in antidepressant metabolism rates, leading to hope regarding the use of P450 genotyping to guide treatment. However, evidence that P450 genotypic differences underlie the variation in treatment outcomes is inconclusive. OBJECTIVES: We explored the links between both P450 genotype and serum concentrations of antidepressant with antidepressant side effects, using data from the Genome-Based Therapeutic Drugs for Depression Project (GENDEP), which is a large (n = 868), pharmacogenetic study of depressed individuals treated with escitalopram or nortriptyline. METHODS: Patients were genotyped for the enzymes CYP2C19 and CYP2D6, and serum concentrations of both antidepressant and primary metabolite were measured after 8 weeks of treatment. Side effects were assessed weekly. We investigated associations between P450 genotypes, serum concentrations of antidepressants and side effects, as well as the relationship between P450 genotype and study discontinuation. RESULTS: P450 genotype did not predict total side effect burden (nortriptyline: n = 251, p = 0.5638, β = −0.133, standard error (SE) = 0.229; escitalopram: n = 340, p = 0.9627, β = −0.004, SE = 0.085), study discontinuation (nortriptyline n = 284, hazard ratio (HR) = 1.300, p = 0.174; escitalopram n = 376, HR = 0.870, p = 0.118) or specific side effects. Serum concentrations of antidepressant were only related to a minority of the specific side effects measured: dry mouth, dizziness and diarrhoea. CONCLUSIONS: In this sample where antidepressant dosage is titrated using clinical judgement, P450 genotypes do not explain differences between patients in side effects with antidepressants. Serum drug concentrations appear to only explain variability in the occurrence of a minority of specific side effects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-015-3898-x) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-03-12 2015 /pmc/articles/PMC4480333/ /pubmed/25761838 http://dx.doi.org/10.1007/s00213-015-3898-x Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Investigation Hodgson, Karen Tansey, Katherine E. Uher, Rudolf Dernovšek, Mojca Zvezdana Mors, Ole Hauser, Joanna Souery, Daniel Maier, Wolfgang Henigsberg, Neven Rietschel, Marcella Placentino, Anna Craig, Ian W. Aitchison, Katherine J. Farmer, Anne E. Dobson, Richard J. B. McGuffin, Peter Exploring the role of drug-metabolising enzymes in antidepressant side effects |
title | Exploring the role of drug-metabolising enzymes in antidepressant side effects |
title_full | Exploring the role of drug-metabolising enzymes in antidepressant side effects |
title_fullStr | Exploring the role of drug-metabolising enzymes in antidepressant side effects |
title_full_unstemmed | Exploring the role of drug-metabolising enzymes in antidepressant side effects |
title_short | Exploring the role of drug-metabolising enzymes in antidepressant side effects |
title_sort | exploring the role of drug-metabolising enzymes in antidepressant side effects |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480333/ https://www.ncbi.nlm.nih.gov/pubmed/25761838 http://dx.doi.org/10.1007/s00213-015-3898-x |
work_keys_str_mv | AT hodgsonkaren exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT tanseykatherinee exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT uherrudolf exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT dernovsekmojcazvezdana exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT morsole exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT hauserjoanna exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT souerydaniel exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT maierwolfgang exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT henigsbergneven exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT rietschelmarcella exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT placentinoanna exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT craigianw exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT aitchisonkatherinej exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT farmerannee exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT dobsonrichardjb exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects AT mcguffinpeter exploringtheroleofdrugmetabolisingenzymesinantidepressantsideeffects |